Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Clinical Trial, Phase I

Multicenter Study

Randomized Controlled Trial

Review

Clinical Trial, Phase II

Clinical Trial

Clinical Trial, Phase III

Comparative Study

Case Reports

Webcast

Research Support, N.I.H., Extramural

Publication Year

From

Quick links

Individual year

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2005

2004

2001

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""MAP Kinase Kinase 2""[mesh_terms]

18 Results

Searching titles within these results

Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.

Nuggehally R Srinivas

European journal of drug metabolism and pharmacokinetics 2018;43(4):373-382

Full Text

Abstract

MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.

Alfredo Di Leo, Brian I Carr, Michele Barone, Antonio Facciorusso, Raffaele Licinio

Expert review of gastroenterology & hepatology 2016;9(7):993-1003

Full Text

Abstract

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

Oliver von Richter, Giorgio Massimini, Holger Scheible, Istvan Udvaros, Andreas Johne

British journal of clinical pharmacology 2017;82(6):1498-1508

Free Full Text

Abstract

Multiple café au lait spots in familial patients with MAP2K2 mutation.

Toshiki Takenouchi, Atsushi Shimizu, Chiharu Torii, Rika Kosaki, Takao Takahashi, Hideyuki Saya, Kenjiro Kosaki

American journal of medical genetics. Part A 2014;164A(2):392-6

Full Text

Abstract

BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine.

Yuexi Gu, Mikko Helenius, Kristiina Väänänen, Daria Bulanova, Jani Saarela, Anna Sokolenko, John Martens, Evgeny Imyanitov, Sergey Kuznetsov

Scientific reports 2018;6():28217

Free Full Text

Abstract

Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.

Holger Scheible, Friedrich Kraetzer, Andreas Marx, Andreas Johne, Elmar Wimmer

Drug metabolism and disposition: the biological fate of chemicals 2018;45(2):174-182

Full Text

Abstract

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

Patricia M Lorusso, Alex A Adjei, Mary Varterasian, Shirish Gadgeel, Joel Reid, David Y Mitchell, Lorelei Hanson, Pamela DeLuca, Laura Bruzek, Jill Piens, Peggy Asbury, Keri Van Becelaere, Roman Herrera, Judith Sebolt-Leopold, Mark B Meyer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5281-93

Full Text

Abstract

Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.

Keith Orford, Amita Patnaik, Patricia LoRusso, Lei Fang, Daniele Ouellet, Donna S Cox, Kyri Papadopoulos, John Bauman, Anthony Tolcher, Carolyn Pendry

Journal of clinical pharmacology 2013;53(9):946-54

Full Text

Abstract

A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.

K Watanabe, S Otsu, Y Hirashima, R Morinaga, K Nishikawa, Y Hisamatsu, T Shimokata, M Inada-Inoue, T Shibata, H Takeuchi, T Watanabe, K Tokushige, H Maacke, K Shiaro, Y Ando

Cancer chemotherapy and pharmacology 2017;77(6):1157-64

Full Text

Abstract

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

Bradley J Monk, Rachel N Grisham, Susana Banerjee, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero, Peter Vuylsteke, Robert L Coleman, Felix Hilpert, Amit M Oza, Anneke Westermann, Martin K Oehler, Sandro Pignata, Carol Aghajanian, Nicoletta Colombo, Esther Drill, David Cibula, Kathleen N Moore, Janna Christy-Bittel, Josep M Del Campo, Regina Berger, Christian Marth, Jalid Sehouli, David M O'Malley, Cristina Churruca, Adam P Boyd, Gunnar Kristensen, Andrew Clamp, Isabelle Ray-Coquard, Ignace Vergote

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021;38(32):3753-3762

Free Full Text

Abstract

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.

Anthony W Tolcher, Amita Patnaik, Kyriakos P Papadopoulos, Drew W Rasco, Carlos R Becerra, Alicia J Allred, Keith Orford, Gursel Aktan, Geraldine Ferron-Brady, Nageatte Ibrahim, Jennifer Gauvin, Monica Motwani, Mark Cornfeld

Cancer chemotherapy and pharmacology 2015;75(1):183-9

Full Text

Abstract

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.

Rebecca C Arend, Allison M Davis, Przemyslaw Chimiczewski, David M O'Malley, Diane Provencher, Ignace Vergote, Sharad Ghamande, Michael J Birrer

Gynecologic oncology 2020;156(2):301-307

Full Text

Abstract

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

G R Blumenschein, E F Smit, D Planchard, D-W Kim, J Cadranel, T De Pas, F Dunphy, K Udud, M-J Ahn, N H Hanna, J-H Kim, J Mazieres, S-W Kim, P Baas, E Rappold, S Redhu, A Puski, F S Wu, P A Jänne

Annals of oncology : official journal of the European Society for Medical Oncology 2016;26(5):894-901

Free Full Text

Abstract

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Jeffrey R Infante, Leslie A Fecher, Gerald S Falchook, Sujatha Nallapareddy, Michael S Gordon, Carlos Becerra, Douglas J DeMarini, Donna S Cox, Yanmei Xu, Shannon R Morris, Vijay G R Peddareddigari, Ngocdiep T Le, Lowell Hart, Johanna C Bendell, Gail Eckhardt, Razelle Kurzrock, Keith Flaherty, Howard A Burris, Wells A Messersmith

The Lancet. Oncology 2012;13(8):773-81

Full Text

Abstract

Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists.

Elena Riboldi, Giada Frascaroli, Pietro Transidico, Walter Luini, Sergio Bernasconi, Francesca Mancini, Angelo Guglielmotti, Claudio Milanese, Mario Pinza, Silvano Sozzani, Alberto Mantovani

British journal of pharmacology 2004;140(2):377-83

Free Full Text

Abstract

Results: 1 – 15 / 18

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""MAP Kinase Kinase 2""[mesh_terms]

Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.

MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

Multiple café au lait spots in familial patients with MAP2K2 mutation.

BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine.

Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer.

A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists.

Results for
""MAP Kinase Kinase 2""[mesh_terms]